Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 24:11:487.
doi: 10.3389/fimmu.2020.00487. eCollection 2020.

The Role of PD-1 in Acute and Chronic Infection

Jil M Jubel  1 , Zachary R Barbati  2 , Christof Burger  1 , Dieter C Wirtz  1 , Frank A Schildberg  1
Affiliations
Review

The Role of PD-1 in Acute and Chronic Infection

Jil M Jubel et al. Front Immunol. .

Abstract

PD-1 as an immune checkpoint molecule down-regulates T cell activity during immune responses in order to prevent autoimmune tissue damage. In chronic infections or tumors, lasting antigen-exposure leads to permanent PD-1 expression that can limit immune-mediated clearance of pathogens or degenerated cells. Blocking PD-1 can enhance T cell function; in cancer treatment PD-1 blockade is already used as a successful therapy. However, the role of PD-1 expression and blocking in the context of acute and chronic infections is less defined. Building on its success in cancer therapy leads to the hypothesis that blocking PD-1 in infectious diseases is also beneficial in acute or chronic infections. This review will focus on the role of PD-1 expression in acute and chronic infections with virus, bacteria, and parasites, with a particular focus on recent studies regarding PD-1 blockade in infectious diseases.

Keywords: PD-1; PD-L1; PD-L2; T cell exhaustion; acute infection; checkpoint inhibitor; chronic infection; infectious disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T cell differentiation during acute vs. chronic infections. When pathogenic peptides are presented by major histocompatibility complex (MHC) to naive T cells during infection, corresponding T cells are activated and differentiate into effector T cells specific for the pathogen. During acute infection, the immune system is able to specifically target the pathogen and eradicate it. During this process, memory T cells develop and confer immunological memory against recurrent infection. In contrast, during chronic infection the persistent load of pathogenic peptides leads to permanent stimulation of T cells, which promotes T cell exhaustion. T cell exhaustion is in part defined by the upregulation of coinhibitory receptors such as PD-1, LAG-3, and Tim-3. These receptors inhibit T cells by decreasing IL-2 production, proliferation, and the threshold for apoptosis.
Figure 2
Figure 2
(A) PD-1 signaling pathway. The binding of PD-L1 or PD-L2 to its receptor PD-1 results in the phosphorylation of PD-1's ITSM and ITIM tyrosine motifs, which are located on its cytoplasmic domain. Phosphorylation leads to the recruitment of protein tyrosine phosphatases, such as SHP2. SHP2 subsequently inhibits two important pathways: One, it competes with kinases to prevent the activation of PI3K by phosphorylation. This inhibits phosphorylation of PIP2 to PIP3, thereby inhibiting Akt activation. Deactivation of serine-threonine kinase Akt reduces T cell proliferation, increases apoptosis, and promotes T cell exhaustion. Effector functions such as cytokine production and cytolytic function are also reduced. Two, SHP2 inhibits the Ras-MEK-ERK pathway. Dephosphorylation of ZAP-70 and LCK antagonize the positive downstream effects of the MHC-TCR pathway, leading to deactivation of PLC-γ, Ras-GRP1 and MEK/ERK1. ERK1 normally activates transcription factors that induce T cell proliferation and differentiation. Thus, decreased ERK1 activation reduces proliferation and differentiation potential. (B) Blockade of PD-1. In the presence of a PD-1 blocking antibody, the engagement of PD-1 and its ligands is inhibited. Consequently, SHP2 is not activated and neither PI3K/Akt pathway nor Ras-MEK-ERK pathway are repressed. Activated AKT and ERK support T cell cytokine production, proliferation, and differentiation. Furthermore, PD-1 blockade reduces T cell exhaustion and the rate of apoptosis. ITSM, immunoreceptor tyrosine-based switch motif; ITIM: immunoreceptor tyrosine-based inhibition motif; SHP2, Src homology region 2 domain-containing phosphatase 2; PI3K, phosphoinositide 3-kinase; PIP2, phosphoinositide-3,4-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; Ras, rat sarcoma; MEK, MAK-/ERK-kinase; ERK1, extracellular-signal regulated kinases 1; Zap-70, zeta-chain-associated protein kinase 70; LCK, lymphocyte-specific protein tyrosine kinase; PLC-γ, Phosphoinositide phospholipase C-γ.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bucktrout SL, Bluestone JA, Ramsdell F. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. (2018) 10:79. 10.1186/s13073-018-0588-4 - DOI - PMC - PubMed
    1. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. (2016) 44:955–72. 10.1016/j.immuni.2016.05.002 - DOI - PMC - PubMed
    1. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. . CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. (2005) 25:9543–53. 10.1128/MCB.25.21.9543-9553.2005 - DOI - PMC - PubMed
    1. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. (2003). 14:265–73. 10.1016/S1359-6101(03)00025-X - DOI - PubMed
    1. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. . The CD28 signaling pathway regulates glucose metabolism. Immunity. (2002) 16: 769–77. 10.1016/S1074-7613(02)00323-0 - DOI - PubMed

Publication types

MeSH terms